Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD

Phase

Condition

Attention Deficit/hyperactivity Disorder (Adhd - Adults)

Williams Syndrome

Bipolar Disorder

Treatment

N/A

Clinical Study ID

NCT00305370

GPPG03-325b

Ages 8-17
All Genders

Study Summary

There is a scarcity of clinical trials assessing the effects of medications in children with bipolar disorder. This study aims to assess the efficacy of Aripiprazole associated with Methylphenidate (MPH)for the treatment of children and adolescents with bipolar disorder comorbid with ADHD who improve in maniac symptoms while receiving aripiprazole but did not have an adequate response in ADHD symptoms. The study design is a 4-week randomized, double blind, cross-over group trial. Patients were randomized to aripiprazole + MPH or aripiprazole

placebo. The main hypothesis is: Aripiprazole + MPH will significantly reduce ADHD scores compared to aripiprazole + placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age: 8 -17
BD type I or II comorbid with ADHD
Reduction of maniac symptoms (30% reduction in the YMRS scores and/or CGI scores ≤ 2)while using aripiprazole during a previous study (NCT00116259)without improvement ofADHD symptoms (reduction in ADHD symptoms < 30% in the SNAP-IV). Those receivingplacebo in the previous protocol will receive a 6- week open label treatment witharipiprazole. The same threshold for reducing maniac symptoms and absence of responsein ADHD symptoms will be used.

Exclusion

Exclusion Criteria:

IQ < 70
Pregnancy or absence of a contraceptive method in fertile girls
Diagnoses: pervasive development disorder, schizophrenia, drug abuse or dependency
Risk of suicide or homicide
Clinical condition that might interfere in the study
Known sensibility to aripiprazole

Study Design

August 01, 2005

March 31, 2008

Study Description

Bipolar disorder (BD) is a chronic disorder that severely affects the normal development of children and adolescents. The disorder is associated with high rates of suicide and high-risk behaviors like sexual promiscuity and drug abuse. Bipolar disorder in children is also associated with high rates of comorbidity, especially with Attention-Deficit Hyperactivity Disorder (ADHD). There is a scarcity of clinical trials assessing the effects of medications in children with BD. Moreover, the frequent presence of comorbid ADHD might determine lower response to treatment. Aripiprazole is a novel anti-psychotic drug. Its mechanism of action seems to be related to a stabilization of dopaminergic transmission, acting as a partial agonist especially in dopaminergic D2 receptors. It also has effects in 5-HT1a serotonergic receptors. Thus, it might have a promising effect in children and adolescents with comorbid BD and ADHD. A retrospective chart review, recently published, suggests the efficacy of this drug in children with BD. This study aims to assess the efficacy of Aripiprazole associated with Methylphenidate (MPH) for the treatment of 20 children and adolescents (age range: 8 to 17 years-old) with Bipolar Disorder comorbid with ADHD who improve in maniac symptoms while receiving aripiprazole but did not have an adequate response in ADHD symptoms. The study design is a 4-week randomized, double blind, cross-over group trial. Patients were randomized to aripiprazole + MPH or aripiprazole + placebo. The hypotheses are: 1) Aripiprazole + MPH will significantly reduce ADHD scores compared to aripiprazole + placebo. 2) Patients receiving aripiprazole + MPH will not deteriorate in maniac symptoms.

Connect with a study center

ADHD Outpatient Program
Porto Alegre, RS 90035-003
Brazil
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.